IP Library Granted Patent US 9,782,348
Granted Patent B2
US 9,782,348 · App. 15/213,285 · Granted Oct 10, 2017

Ingestible formulations for transient, noninvasive reduction of gastric volume

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,782,348
App. No.
15/213,285
Granted
Oct 10, 2017
Kind
B2
Abstract

Provided are ingestible polymeric formulations and oral dosage forms for the reduction of gastric volume in the treatment of overweight and obese patients. The formulation includes an acid-sensitive, gelatin coating over a dehydrated hydrophilic polymer. When ingested, the acid-sensitive coating is quickly dissolved by gastric secretions and the hydrophilic polymer is exposed to the aqueous environment of the gastric milieu. The polymer absorbs water and expands to the point that will not allow the polymer to pass beyond the pyloric valve, and the expanded polymer is therefore trapped in the stomach.

Claims (6)

1. A method of creating a sensation of fullness in a stomach of a patient, comprising:

ingesting one or more ingestible tablets formed in a packed mass into the stomach, the ingestible tablets comprising a biocompatible polymer in combination with a solubilizer/stabilization propylene glycol alginate agent which is adapted to maintain the polymer as a firm solid, wherein the polymer further includes one or more lipase-sensitive, fatty acid-like polymerizable groups or cross-linking groups;

increasing a size of the polymer by absorbing water from gastric fluid such that the polymer is maintained within the stomach for at least 2 hours and a sensation of fullness is induced in the patient without releasing a drug which induces the sensation;

disintegrating an acid-sensitive gelatin coating such that the polymer disintegrates in the gastric fluid and disperses in the stomach at a first degradation rate; and

further disintegrating the polymer within an intestinal tract of the patient upon exposure to an intestinal enzyme or an intestinal pH at a second degradation rate which is higher than the first degradation rate, wherein the second degradation rate is sufficiently rapid to substantially prevent a small bowel obstruction by the polymer.

2. The method of claim 1 wherein the polymer is selected from the group consisting of polyvinyl alcohol, poly(ethyloxazoline), polyvinylacetate-polyvinylalcohol copolymers, poly(2-hydroxyethylacrylate-), poly(2-hydroxyethylmethacrylate, polyacrylic acid, and copolymers thereof, polysaccharides, water soluble proteins, and polynucleic acids.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Sep 27, 2019
From: PACIFIC WESTERN BANK
To: BARONOVA, INC.
Reel/Frame 050521/0180 →
SECURITY INTEREST Recorded Nov 29, 2018
From: BARONOVA, INC.
To: PACIFIC WESTERN BANK
Reel/Frame 047626/0955 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 040829 FRAME: 0687. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jun 19, 2018
From: BURNETT, DANIEL R.; EDELMAN, PETER G.
To: POLYMORFIX, INC.
Reel/Frame 046392/0922 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2017
From: BURNETT, DANIEL R.; EDELMAN, PETER G.
To: POLYMOFIX, INC.
Reel/Frame 040829/0687 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2017
From: POLYMORFIX, INC.
To: MEDVENTURE ASSOCIATES IV
Reel/Frame 040831/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2017
From: POLYMORFIX, INC.
To: MEDVENTURE ASSOCIATES IV, L.P.
Reel/Frame 040831/0377 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2017
From: MEDVENTURE ASSOCIATES IV, L.P.
To: BURNETT, DANIEL R.
Reel/Frame 040831/0683 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2017
From: BURNETT, DANIEL R.
To: BARONOVA, INC.
Reel/Frame 040831/0745 →